AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18337052 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 16595210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronuclear morphology (group 1)
Number of subjects: 330
Study 16595210 — intervention group
Group type: COMPARATOR
Intervention: Early cleavage status (group 2)
Number of subjects: 330
Study 16595210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A zygotes from each group
Number of subjects: 330
Study 16595210 — intervention group
Group type: COMPARATOR
Intervention: Subgroup C zygotes from each group
Number of subjects: 330
Study 12939417 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (maximum tolerated dose up to 800 mg/day)
Number of subjects: 296
Study 12939417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 11032270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) added to ropivacaine (40 ml 0.75%)
Number of subjects: 50
Study 11032270 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml) added to ropivacaine (40 ml 0.75%)
Number of subjects: 50
Study 8822590 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mmol MgSO4 intravenous bolus over 15 min followed by 3 mmol MgSO4/h
Number of subjects: 14
Study 1427457 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered calcium heparin (every 8 h)
Number of subjects: 59
Study 1427457 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium heparin
Number of subjects: 59
Study 1427457 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered calcium heparin
Number of subjects: 59
Study 4084435 — intervention group
Group type: EXPERIMENTAL
Intervention: Construct group (psychological reconstruction programme)
Number of subjects: 48
Study 4084435 — intervention group
Group type: COMPARATOR
Intervention: Technique group (behaviour modification for fluent speech)
Number of subjects: 48
Study 29572087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-source computed tomography (CT)
Number of subjects: 54
Study 29572087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preimplant knowledge of venous anatomy)
Number of subjects: 54
Study 27454383 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose AZD9773
Number of subjects: 300
Study 27454383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AZD9773
Number of subjects: 300
Study 27454383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24749369 — intervention group
Group type: EXPERIMENTAL
Intervention: UC‐MSCs adjuvant treatment group (n=17)
Number of subjects: 37
Study 24749369 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (control group, n=20)
Number of subjects: 37
Study 22971864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral Acyclovir
Number of subjects: 42
Study 22971864 — intervention group
Group type: COMPARATOR
Intervention: Oral Erythromycin (standard dose)
Number of subjects: 42
Study 20159122 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 44
Study 20159122 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 44
Study 19065363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone Slow Release Pessary (Propess)
Number of subjects: 120
Study 19065363 — intervention group
Group type: COMPARATOR
Intervention: Gel (Prostin)
Number of subjects: 120
Study 16132903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lenograstim (10 microg/kg once a day)
Number of subjects: 40
Study 16132903 — intervention group
Group type: COMPARATOR
Intervention: Split-dose lenograstim (5 microg/kg twice a day)
Number of subjects: 40
Study 16132903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lenograstim
Number of subjects: 40
Study 16132903 — intervention group
Group type: COMPARATOR
Intervention: Split-dose lenograstim
Number of subjects: 40
Study 12193081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary BQ‐123 (6 micromol)
Number of subjects: 22
Study 12193081 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 9457019 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 0
Study 9457019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel function regulator
Number of subjects: 0
Study 9457019 — intervention group
Group type: EXPERIMENTAL
Intervention: Late childhood treatment
Number of subjects: 0
Study 7614494 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 26
Study 7614494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipradilol
Number of subjects: 26
Study 7614494 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 26
Study 2694825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecobalamin (500 gamma i.m., 3 times a week for 4 weeks)
Number of subjects: 17
Study 2694825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecobalamin administered group
Number of subjects: 17
Study 2694825 — intervention group
Group type: COMPARATOR
Intervention: Non-administered group
Number of subjects: 17
Study 2694825 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bladder pressure
Number of subjects: 17
Study 2694825 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall maximum urethral pressure
Number of subjects: 17
Study 2694825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with residual urine less than 50 ml
Number of subjects: 17
Study 2694825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with residual urine reduced to less than 50 ml at 3 months
Number of subjects: 17
Study 2694825 — intervention group
Group type: COMPARATOR
Intervention: Comparison between mecobalamin and non-administered groups
Number of subjects: 17
Study 65508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromoglycate (cromolyn sodium)
Number of subjects: 28
Study 65508 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 28
Study 65508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen (cromoglycate and theophylline)
Number of subjects: 28
Study 65508 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and combined regimen
Number of subjects: 28
Study 6976790 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-isopropyl phenol (Diprivan) 2.0 mg kg‐1
Number of subjects: 0
Study 6976790 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-isopropyl phenol (Diprivan) <1.75 mg kg‐1
Number of subjects: 0
Study 6976790 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-isopropyl phenol (Diprivan) 1.5 - 2.0 mg kg‐1
Number of subjects: 0
Study 6976790 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-isopropyl phenol (Diprivan) 2.5 mg kg‐1
Number of subjects: 0
Study 6976790 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-isopropyl phenol (Diprivan) (any dose)
Number of subjects: 0
Study 30696552 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing enzymes and proteins
Number of subjects: 229
Study 30696552 — intervention group
Group type: COMPARATOR
Intervention: Commercial control toothpaste
Number of subjects: 229
Study 29482632 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice
Number of subjects: 45
Study 29482632 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BI (NIAAA Clinician's Guide)
Number of subjects: 45
Study 29482632 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-enhanced BI
Number of subjects: 45
Study 29482632 — intervention group
Group type: EXPERIMENTAL
Intervention: All three BI protocols
Number of subjects: 45
Study 26852138 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 61
Study 26852138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based multitask training (1-hour supervised group classes once weekly for 6 months)
Number of subjects: 134
Study 24212920 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based multitask training
Number of subjects: 134
Study 24212920 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention, maintained usual lifestyle habits)
Number of subjects: 134
Study 22473508 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact Bolus (CB) protocol: iomeprol 400mgI/mL, 100 mL, 4 mL/sec
Number of subjects: 64
Study 22473508 — intervention group
Group type: COMPARATOR
Intervention: Standard Bolus (SB) protocol: iomeprol 300mgI/mL, 134 mL, 4 mL/sec
Number of subjects: 64
Study 20854047 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 115
Study 20854047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 115
Study 20854047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 20854047 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg and Tiotropium 18 μg
Number of subjects: 115
Study 17986038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with midazolam, ketamine, and propofol (MKP group)
Number of subjects: 655
Study 17986038 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with propofol, vecuronium, and isoflurane (GET group)
Number of subjects: 655
Study 16301368 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating technology (ODT)
Number of subjects: 36
Study 16301368 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet
Number of subjects: 36
Study 11948884 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioSeal (AS)
Number of subjects: 157
Study 11948884 — intervention group
Group type: EXPERIMENTAL
Intervention: VasoSeal (VS)
Number of subjects: 157
Study 9719052 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (20 mmol/d magnesium in the form of magnesium oxide)
Number of subjects: 60
Study 9719052 — intervention group
Group type: COMPARATOR
Intervention: Control period (no magnesium supplementation)
Number of subjects: 60
Study 7544554 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin adipinate (5 to 20 mg)
Number of subjects: 95
Study 7544554 — intervention group
Group type: COMPARATOR
Intervention: Traditional drugs (proserine, pituitrin, cerucal)
Number of subjects: 95
Study 7544554 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin adipinate
Number of subjects: 95
Study 2782569 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml water 2 hours before surgery
Number of subjects: 150
Study 2782569 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml water 2 hours before surgery + intramuscular morphine 0.15 mg/kg and promethazine 0.5 mg/kg one hour before operation
Number of subjects: 150
Study 2782569 — intervention group
Group type: COMPARATOR
Intervention: Control group (overnight fast)
Number of subjects: 150
Study 906892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cerebrospinal irradiation
Number of subjects: 22
Study 906892 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cerebrospinal irradiation (Control)
Number of subjects: 22
Study 31891295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 102
Study 31891295 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 200 mg/Acetaminophen 216.7 mg
Number of subjects: 102
Study 28013387 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (CurraNZ™) 600 mg day‐1
Number of subjects: 15
Study 28013387 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (CurraNZ™) 900 mg day‐1
Number of subjects: 15
Study 28013387 — intervention group
Group type: COMPARATOR
Intervention: Control (no NZBC)
Number of subjects: 15
Study 25976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100mg, twice a day for eight weeks)
Number of subjects: 52
Study 25976576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day for eight weeks)
Number of subjects: 52
Study 25976576 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q10 and Placebo
Number of subjects: 52
Study 24021291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) infused IV at 125 mg over 10 minutes (Study 1)
Number of subjects: 240
Study 24021291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) infused IV at 62.5 mg over 30 minutes (Study 2)
Number of subjects: 240
Study 24021291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin-bound iron (TBI) from SFGC (Study 1)
Number of subjects: 240
Study 21300704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild CKD (60-90 mL/min/1.73 m²)
Number of subjects: 180
Study 21300704 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe CKD (<60 mL/min/1.73 m²)
Number of subjects: 180
Study 21300704 — intervention group
Group type: COMPARATOR
Intervention: Non-CKD (≥90 mL/min/1.73 m²)
Number of subjects: 180
Study 19422410 — intervention group
Group type: EXPERIMENTAL
Intervention: High light intensity (600 lux)
Number of subjects: 36
Study 19422410 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium light intensity (200 lux)
Number of subjects: 36
Study 19422410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low light intensity (50 lux)
Number of subjects: 36
Study 19422410 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 17340897 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Loaded (EL) implants
Number of subjects: 17
Study 17340897 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loaded (DL) implants
Number of subjects: 17
Study 17340897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EL and DL implants
Number of subjects: 17
Study 15003147 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/d of haloperidol
Number of subjects: 40
Study 15003147 — intervention group
Group type: COMPARATOR
Intervention: 8 mg/d of haloperidol
Number of subjects: 40
Study 11107921 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral salpingo‐oophorectomy coupled with comprehensive surgical staging
Number of subjects: 0
Study 11107921 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy and bilateral salpingo‐oophorectomy
Number of subjects: 0
Study 11107921 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 11107921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study 11107921 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ploidy
Number of subjects: 0
Study 9263114 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (GTX) with adequate doses of compatible leukocytes
Number of subjects: 8
Study 9263114 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study 8472980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg twice daily
Number of subjects: 24
Study 8472980 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily
Number of subjects: 24
Study 8472980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate
Number of subjects: 24
Study 8472980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine or ranitidine bismuth citrate
Number of subjects: 24
Study 3814227 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g L-aspartic acid for 7 days
Number of subjects: 31
Study 3814227 — intervention group
Group type: COMPARATOR
Intervention: 50 mg chlorpromazine + 60 mg diazepam daily
Number of subjects: 31
Study 31531601 — intervention group
Group type: EXPERIMENTAL
Intervention: TVS RT‐3D‐HyCoSy
Number of subjects: 83
Study 28181973 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 46
Study 28181973 — intervention group
Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 46
Study 28181973 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 46
Study 26275472 — intervention group
Group type: EXPERIMENTAL
Intervention: Free glasses, education on their use, and a teacher incentive
Number of subjects: 728
Study 26275472 — intervention group
Group type: COMPARATOR
Intervention: Glasses prescriptions only
Number of subjects: 728
Study 23019151 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 468
Study 22852118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin, 1.0 g i.v., once postoperatively
Number of subjects: 160
Study 22852118 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate, 1000 mg orally for 7 days postoperatively
Number of subjects: 160
Study 19161365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (walking for 40 min at 50-60% VO(2peak))
Number of subjects: 24
Study 19161365 — intervention group
Group type: COMPARATOR
Intervention: Control (sitting quietly for 40 min)
Number of subjects: 24
Study 19161365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise and control
Number of subjects: 24
Study 16948661 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 1.8 mL
Number of subjects: 31
Study 16948661 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltration of 0.9 mL plus lingual infiltration of 0.9 mL
Number of subjects: 31
Study 12597221 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistive training program for torso rotation
Number of subjects: 20
Study 9884382 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-hirudin) regimen A1 (0.4 mg/kg bolus and then 0.15 mg/kg/h)
Number of subjects: 82
Study 9884382 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-hirudin) regimen A2 (0.2 mg/kg bolus and then 0.1 mg/kg/h)
Number of subjects: 82
Study 9884382 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-hirudin)
Number of subjects: 82
Study 8905422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at 1 mg/kg per hour over 24 h
Number of subjects: 24
Study 8905422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 24
Study 1892185 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW MAG (535 mg every 4 hours)
Number of subjects: 75
Study 1892185 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ritodrine (20 mg every 4 hours)
Number of subjects: 75
Study 1892185 — intervention group
Group type: COMPARATOR
Intervention: no therapy (control)
Number of subjects: 75
Study 6357256 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest physiotherapy
Number of subjects: 102
Study 6357256 — intervention group
Group type: COMPARATOR
Intervention: No physiotherapy (Control)
Number of subjects: 102
Study 30276833 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg of beraprost (three tablets)
Number of subjects: 29
Study 28933605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early isometric loading of the rotator cuff
Number of subjects: 30
Study 28933605 — intervention group
Group type: COMPARATOR
Intervention: Primary passive motion
Number of subjects: 30
Study 26669795 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education
Number of subjects: 590
Study 26669795 — intervention group
Group type: COMPARATOR
Intervention: In-person group education
Number of subjects: 590
Study 25182454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin subcutaneously twice daily, initial weight-based dosing: infants (< 12 months) 150 IU kg(‐1), children (1‐12 years) 125 IU kg(‐1), adolescents (13‐18 years) 100 IU kg(‐1)
Number of subjects: 18
Study 23211656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including counselling on GWG, physical activity, and healthy eating at five routine visits
Number of subjects: 399
Study 23211656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 399
Study 23211656 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 399
Study 20705432 — intervention group
Group type: EXPERIMENTAL
Intervention: arthrocentesis followed by intra‐articular injection of sodium hyaluronate (SH)
Number of subjects: 25
Study 20705432 — intervention group
Group type: COMPARATOR
Intervention: arthrocentesis
Number of subjects: 25
Study 16936327 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg qd
Number of subjects: 1207
Study 16936327 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg qd
Number of subjects: 1207
Study 16936327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 17012878 — intervention group
Group type: EXPERIMENTAL
Intervention: Menactra (MCV-4) vaccine
Number of subjects: 220
Study 17012878 — intervention group
Group type: COMPARATOR
Intervention: Menomune (PSV-4) vaccine
Number of subjects: 220
Study 15259387 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive group
Number of subjects: 33
Study 15259387 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative group
Number of subjects: 33
Study 10421303 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches prescribed by GPs for up to 12 weeks
Number of subjects: 30
Study 10421303 — intervention group
Group type: EXPERIMENTAL
Intervention: GP counselling with nicotine-patch treatment
Number of subjects: 30
Study 10421303 — intervention group
Group type: COMPARATOR
Intervention: GP counselling alone
Number of subjects: 30
Study 7605024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (3% during transition to 1.24 MAC)
Number of subjects: 21
Study 7605024 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (9% during transition to 1.24 MAC)
Number of subjects: 21
Study 7605024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.41, 0.83, and 1.24 MAC)
Number of subjects: 21
Study 7605024 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (0.41, 0.83, and 1.24 MAC)
Number of subjects: 21
Study 7605024 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (greater minimum alveolar concentration)
Number of subjects: 21
Study 7605024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (greater minimum alveolar concentration)
Number of subjects: 21
Study 1387253 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 50
Study 1387253 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50